Clinical Trial

Chinese Medicinal Component Relieves CIPN and Mitochondria Function

Withdrawn
View on ClinicalTrials.gov →
Why the trial stopped
Initial prep showed that formulation, QC, and cost for high-dose paeonol/Cortex Moutan exceeded the budget. Also, recruiting patients with chemotherapy-induced peripheral neuropathy was limited. To ensure safety, enrollment did not officially launch.
Summary
A randomized controlled trial was designed and conducted to confirm whether oral administration of the herb Moutan Cortex, which contains paeonol, can alleviate peripheral neuropathy in paclitaxel-treated cancer patients. This research project will validate our new preliminary findings demonstrating the neuroprotective effects after paclitaxel treatment. Importantly, our data are expected to elucidate the way Moutan Cortex induces neuroprotection in the clinical setting and provide a scientific basis for the development of new approaches to treat CIPN.
Trial Details
NCT Number NCT07693374
Lead Sponsor Taiwan Municipal An-Nan Hospital-China Medical University
Collaborators: China Medical University, Taiwan
Conditions Breast Cancer, Chemotherapy-induced Peripheral Neuropathy (CIPN)
Start Date 2022-08-01
Primary Completion 2025-08-30 (estimated)
Study Completion 2025-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-09